Skip to main content

Table 2 PASI response rates and NNT at Week 24 among the overall population

From: Network meta-analysis and cost per responder of targeted Immunomodulators in the treatment of active psoriatic arthritis

Treatment

PASI75

PASI90

Response (95% CrI)

NNT (95% CrI)

Response (95% CrI)

NNT (95% CrI)

Placebo

7.6% (5.2%, 10.8%)

–

2.9% (1.8%, 4.5%)

–

Adalimumab

72.7% (54.0%, 86.7%)

1.5 (1.3, 2.1)

55.5% (36.0%, 74.3%)

1.9 (1.4, 3.0)

Apremilast

23.9% (14.1%, 36.5%)

6.2 (3.6, 13.3)

12.0% (6.1%, 21.0%)

11.0 (5.7, 26.5)

Certolizumab pegol

45.6% (31.6%, 60.4%)

2.6 (1.9, 4.0)

28.4% (17.4%, 42.1%)

3.9 (2.6, 6.7)

Etanercept

26.0% (12.9%, 44.1%)

5.5 (2.8, 16.7)

13.4% (5.5%, 27.1%)

9.6 (4.2, 34.1)

Golimumab

74.1% (56.1%, 87.7%)

1.5 (1.3, 2.0)

57.2% (37.9%, 75.8%)

1.8 (1.4, 2.8)

Infliximab

77.1% (60.5%, 89.5%)

1.4 (1.2, 1.9)

61.0% (42.4%, 78.8%)

1.7 (1.3, 2.5)

Secukinumab 150 mg

50.3% (36.1%, 65.3%)

2.3 (1.8, 3.4)

32.4% (20.6%, 47.2%)

3.4 (2.3, 5.5)

Secukinumab 300 mg

60.4% (39.7%, 79.2%)

1.9 (1.4, 3.0)

42.3% (23.6%, 63.7%)

2.5 (1.7, 4.8)

Ustekinumab 45 mg

51.2% (37.5%, 64.8%)

2.3 (1.8, 3.2)

33.2% (21.8%, 46.6%)

3.3 (2.3, 5.1)

Ustekinumab 90 mg

58.2% (44.7%, 70.8%)

2.0 (1.6, 2.6)

39.9% (27.5%, 53.4%)

2.7 (2.0, 4.0)

  1. CrI credible interval, NNT number needed to treat
Back to article page

BMC Rheumatology

ISSN: 2520-1026

Contact us